Language Selector

    Call for Testing Compounds Against SARS-CoV-2

    Published on 02 April 2020
    Author: Riccardo Scarinci, National Contact Point for ICT

    The project Exscalate4CoV (E4C) invites organisations to submit proposals for screening of their compounds for efficacy profiling on the E4C Biology platforms.

    The project E4C uses supercomputers in the search of therapies (small molecule drugs) against SARS-CoV-2.
    In particular E4C has a pipeline of phenotypic and target based screens to evaluate the efficacy of repurposed, commercial and de-novo designed compounds.

    E4C invites organisations to submit proposals for screening of their compounds for efficacy profiling on the E4C Biology platforms.

    The minimum requirements for providing physical compounds are:

    • rational reason for selection;
    • a positive review by E4C medicinal chemists;
    • compounds have not already been analysed in E4C or reported assays;
    • physical material is available (10mM in 100% DMSO, 20 microliters volume).

    Full criteria and conditions are defined in the “Drug-Box” submission portal on the E4C website.